{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:41:25Z","timestamp":1791031285956,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Trace Elements in Medicine and Biology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.jtemb.2012.03.009","type":"journal-article","created":{"date-parts":[[2012,5,6]],"date-time":"2012-05-06T02:41:45Z","timestamp":1336272105000},"page":"127-130","source":"Crossref","is-referenced-by-count":26,"title":["Iron mobilization using chelation and phlebotomy"],"prefix":"10.1016","volume":"26","author":[{"given":"Trond Peder","family":"Flaten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Aaseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Kontoghiorghes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtemb.2012.03.009_bib0005","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMra1004967","article-title":"Iron overload in human disease","volume":"366","author":"Fleming","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtemb.2012.03.009_bib0010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/00365520601075662","article-title":"Hereditary iron and copper deposition: diagnostics, pathogenesis and therapeutics","volume":"42","author":"Aaseth","year":"2007","journal-title":"Scand J Gastroenterol"},{"issue":"22","key":"10.1016\/j.jtemb.2012.03.009_bib0015","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2010-01-251348","article-title":"The inherited diseases of hemoglobin are an emerging global health burden","volume":"115","author":"Weatherall","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtemb.2012.03.009_bib0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/jmg.34.4.275","article-title":"Global prevalence of putative haemochromatosis mutations","volume":"34","author":"Merryweather-Clarke","year":"1997","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.jtemb.2012.03.009_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jhep.2010.03.001","article-title":"EASL clinical practice guidelines for HFE hemochromatosis","volume":"53","author":"European Association for the Study of the Liver","year":"2010","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jtemb.2012.03.009_bib0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/aje\/154.3.193","article-title":"HFE gene and hereditary hemochromatosis: a HuGE review","volume":"154","author":"Hanson","year":"2001","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1016\/j.jtemb.2012.03.009_bib0035","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/003655201750422747","article-title":"Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons","volume":"36","author":"\u00c5sberg","year":"2001","journal-title":"Scand J Gastroenterol"},{"issue":"23","key":"10.1016\/j.jtemb.2012.03.009_bib0040","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMra031573","article-title":"Hereditary hemochromatosis \u2013 a new look at an old disease","volume":"350","author":"Pietrangelo","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtemb.2012.03.009_bib0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev-med-050109-142444","article-title":"Hepcidin and disorders of iron metabolism","volume":"62","author":"Ganz","year":"2011","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.jtemb.2012.03.009_bib0050","first-page":"55","article-title":"Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects","volume":"35","author":"Bothwell","year":"1998","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.jtemb.2012.03.009_bib0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00002281-200101000-00013","article-title":"Arthropathy in hereditary hemochromatosis","volume":"13","author":"von Kempis","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jtemb.2012.03.009_bib0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00003086-199804000-00014","article-title":"Hemochromatosis of the foot and ankle. Report of three cases and review of the literature","volume":"349","author":"Bailey","year":"1998","journal-title":"Clin Orthop"},{"issue":"4","key":"10.1016\/j.jtemb.2012.03.009_bib0065","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1053\/gast.1996.v110.pm8613000","article-title":"Long-term survival in patients with hereditary hemochromatosis","volume":"110","author":"Niederau","year":"1996","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.jtemb.2012.03.009_bib0070","doi-asserted-by":"crossref","first-page":"932","DOI":"10.7326\/0003-4819-129-11_Part_2-199812011-00003","article-title":"Management of hemochromatosis","volume":"129","author":"Barton","year":"1998","journal-title":"Ann Intern Med"},{"issue":"7790","key":"10.1016\/j.jtemb.2012.03.009_bib0075","first-page":"218","article-title":"Diagnosis and management of hereditary haemochromatosis","volume":"342","author":"van Bokhoven","year":"2011","journal-title":"Br Med J"},{"issue":"8","key":"10.1016\/j.jtemb.2012.03.009_bib0080","first-page":"865","article-title":"Juvenile hemochromatosis associated with \u03b2-thalassemia treated by phlebotomy and recombinant human erythropoietin","volume":"85","author":"De Gobbi","year":"2000","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtemb.2012.03.009_bib0085","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMct1004810","article-title":"Iron-chelating therapy for transfusional iron overload","volume":"364","author":"Brittenham","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtemb.2012.03.009_bib0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0955-3886(00)00089-8","article-title":"Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1)","volume":"23","author":"Kontoghiorghes","year":"2000","journal-title":"Transfus Sci"},{"issue":"5","key":"10.1016\/j.jtemb.2012.03.009_bib0095","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3324\/haematol.12413","article-title":"Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders","volume":"93","author":"Angelucci","year":"2008","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jtemb.2012.03.009_bib0100","first-page":"704","article-title":"Inherited haemoglobin disorders: an increasing global health problem","volume":"79","author":"Weatherall","year":"2001","journal-title":"Bull World Health Organ"},{"issue":"15","key":"10.1016\/j.jtemb.2012.03.009_bib0105","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.2174\/092986711795656117","article-title":"Recent insights on the medicinal chemistry of sickle cell disease","volume":"18","author":"dos Santos","year":"2011","journal-title":"Curr Med Chem"},{"issue":"47","key":"10.1016\/j.jtemb.2012.03.009_bib0110","first-page":"3714","article-title":"Thalassemia in Sweden. Considerably varying therapeutic targets and follow up routines (in Swedish)","volume":"103","author":"Oehmichen","year":"2006","journal-title":"L\u00e4kartidningen"},{"issue":"5","key":"10.1016\/j.jtemb.2012.03.009_bib0115","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1371\/journal.pmed.0030158","article-title":"The effect of \u03b1+-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya","volume":"3","author":"Wambua","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.jtemb.2012.03.009_bib0120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2350-11-21","article-title":"Loss of balancing selection in the \u03b2S globin locus","volume":"11","author":"Salih","year":"2010","journal-title":"BMC Med Genet"},{"issue":"6","key":"10.1016\/j.jtemb.2012.03.009_bib0125","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull World Health Organ"},{"issue":"9","key":"10.1016\/j.jtemb.2012.03.009_bib0130","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1021\/cr980453a","article-title":"Principles and recent developments in chelation treatment of metal intoxication","volume":"99","author":"Andersen","year":"1999","journal-title":"Chem Rev"},{"issue":"7998","key":"10.1016\/j.jtemb.2012.03.009_bib0135","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(76)92035-3","article-title":"Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload","volume":"ii","author":"Hussain","year":"1976","journal-title":"Lancet"},{"issue":"1\u20133","key":"10.1016\/j.jtemb.2012.03.009_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-4274(95)03415-H","article-title":"Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminum chelating drugs","volume":"80","author":"Kontoghiorghes","year":"1995","journal-title":"Toxicol Lett"},{"issue":"1","key":"10.1016\/j.jtemb.2012.03.009_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0362-5478(76)90011-5","article-title":"Pharmacology and therapeutic applications of agents used in heavy metal poisoning","volume":"1","author":"Catsch","year":"1976","journal-title":"Pharmacol Ther [A]"},{"issue":"8","key":"10.1016\/j.jtemb.2012.03.009_bib0150","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00002018-200326080-00003","article-title":"Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine","volume":"26","author":"Kontoghiorghes","year":"2003","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtemb.2012.03.009_bib0155","series-title":"Clinical, biochemical, and nutritional aspects of trace elements","first-page":"477","article-title":"Interactions of essential metals in human physiology","volume":"vol. 6","author":"Kirchgessner","year":"1982"},{"issue":"2","key":"10.1016\/j.jtemb.2012.03.009_bib0160","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.1990.tb07887.x","article-title":"Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1), I. Iron chelation and metabolic studies","volume":"76","author":"Kontoghiorghes","year":"1990","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtemb.2012.03.009_bib0165","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/clpt.1990.147","article-title":"Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"48","author":"Kontoghiorghes","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtemb.2012.03.009_bib0170","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1046\/j.1365-2141.1999.01447.x","article-title":"Transport of 14C-deferiprone in normal, thalassaemic and sickle red blood cells","volume":"105","author":"Shalev","year":"1999","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtemb.2012.03.009_bib0175","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/03630269.2011.576153","article-title":"Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy","volume":"35","author":"Kolnagou","year":"2011","journal-title":"Hemoglobin"},{"key":"10.1016\/j.jtemb.2012.03.009_bib0180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.04240.x","article-title":"Comparison between desferrioxamine and combined therapy with desferrioxamine and deferriprone in iron overloaded thalassaemia patients","volume":"121","author":"Mourad","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtemb.2012.03.009_bib0185","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1749-6632.1998.tb10479.x","article-title":"Survival and disease complications in thalassemia major","volume":"850","author":"Borgna-Pignatti","year":"1998","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.jtemb.2012.03.009_bib0190","first-page":"481","article-title":"Treatment of cardiac iron overload in thalassemia major","volume":"88","author":"Westwood","year":"2003","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtemb.2012.03.009_bib0195","first-page":"489","article-title":"Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis","volume":"88","author":"Piga","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.jtemb.2012.03.009_bib0200","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1532-429X-10-42","article-title":"Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance","volume":"10","author":"Modell","year":"2008","journal-title":"J Cardiovasc Magn Reson"},{"issue":"9369","key":"10.1016\/j.jtemb.2012.03.009_bib0205","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(03)13309-0","article-title":"Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"361","author":"Nisbet-Brown","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jtemb.2012.03.009_bib0210","first-page":"5a","article-title":"Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy","volume":"100","author":"Piga","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtemb.2012.03.009_bib0215","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/03630269.2011.576906","article-title":"A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients","volume":"35","author":"Kontoghiorghes","year":"2011","journal-title":"Hemoglobin"},{"issue":"2","key":"10.1016\/j.jtemb.2012.03.009_bib0220","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14740330903535845","article-title":"Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases","volume":"9","author":"Kontoghiorghes","year":"2010","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"10.1016\/j.jtemb.2012.03.009_bib0225","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0091270003253350","article-title":"Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to \u03b2-thalassemia","volume":"43","author":"Galanello","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jtemb.2012.03.009_bib0230","first-page":"161","article-title":"Prospects for introducing deferiprone as potent pharmaceutical antioxidant","volume":"1","author":"Kontoghiorghes","year":"2009","journal-title":"Front Biosci (Elite Ed)"}],"container-title":["Journal of Trace Elements in Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0946672X1200048X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0946672X1200048X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T11:54:27Z","timestamp":1542974067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0946672X1200048X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":46,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0946672X1200048X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtemb.2012.03.009","relation":{},"ISSN":["0946-672X"],"issn-type":[{"value":"0946-672X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}